(UROY) Uranium Royalty - Ratings and Ratios
Uranium, Royalty, Investments, Mining, Resources
Description: UROY Uranium Royalty
Uranium Royalty Corp (NASDAQ:UROY) is a pure-play uranium royalty company that has strategically accumulated a diversified portfolio of uranium interests across various geographies. The companys royalty interests span multiple projects in Canada, the United States, and Namibia, providing a broad exposure to the global uranium market.
Key Performance Indicators (KPIs) for UROY include its market capitalization of $315.82M USD, indicating a moderate-sized company with potential for growth. The forward P/E ratio of 56.82 suggests that investors are expecting significant growth in earnings. The Return on Equity (RoE) of 0.38 indicates that the company is generating some returns, although this could be improved. The lack of a trailing P/E ratio is likely due to the companys relatively recent incorporation in 2017 and potentially volatile earnings.
From a strategic perspective, UROYs diversified portfolio of uranium interests provides a hedge against project-specific risks and allows the company to benefit from various regional market dynamics. The companys presence in established uranium-producing regions such as Saskatchewan, Canada, and the southwestern United States positions it for potential long-term success. As a royalty company, UROYs business model is designed to generate revenue without directly incurring the operational costs and risks associated with uranium mining.
To further evaluate UROYs performance, it would be essential to monitor its revenue growth, royalty income, and project development milestones. Additionally, tracking industry trends, uranium prices, and the companys competitive positioning within the sector will be crucial in assessing its potential for future growth and returns on investment.
UROY Stock Overview
| Market Cap in USD | 430m |
| Sub-Industry | Coal & Consumable Fuels |
| IPO / Inception | 2021-04-28 |
UROY Stock Ratings
| Growth Rating | 15.4% |
| Fundamental | 31.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 21.8% |
| Analyst Rating | 4.20 of 5 |
UROY Dividends
Currently no dividends paidUROY Growth Ratios
| Growth Correlation 3m | 83.7% |
| Growth Correlation 12m | 4.5% |
| Growth Correlation 5y | -11.2% |
| CAGR 5y | 6.28% |
| CAGR/Max DD 3y | 0.11 |
| CAGR/Mean DD 3y | 0.21 |
| Sharpe Ratio 12m | -0.07 |
| Alpha | 30.82 |
| Beta | 0.933 |
| Volatility | 58.33% |
| Current Volume | 1952.8k |
| Average Volume 20d | 2511.5k |
| Stop Loss | 2.9 (-7.6%) |
| Signal | -0.81 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-5.65m TTM) > 0 and > 6% of Revenue (6% = 935.7k TTM) |
| FCFTA -0.07 (>2.0%) and ΔFCFTA 30.39pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1521 % (prev 394.7%; Δ 1126 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.07 (>3.0%) and CFO -21.6m <= Net Income -5.65m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 233.5 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (133.6m) change vs 12m ago 10.85% (target <= -2.0% for YES) |
| Gross Margin 19.49% (prev 49.24%; Δ -29.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 5.43% (prev 20.82%; Δ -15.39pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -42.66 (EBITDA TTM -5.17m / Interest Expense TTM 124.0k) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 31.71
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -3.74% = -1.87 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 = 2.50 |
| 5. Debt/Ebitda -0.04 = -2.50 |
| 6. ROIC - WACC -11.26% = -12.50 |
| 7. RoE -1.97% = -0.33 |
| 8. Rev. Trend 22.13% = 1.11 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend 12.07% = 0.30 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of UROY shares?
Over the past week, the price has changed by -3.68%, over one month by +16.73%, over three months by +24.60% and over the past year by +44.04%.
Is Uranium Royalty a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of UROY is around 2.79 USD . This means that UROY is currently overvalued and has a potential downside of -11.15%.
Is UROY a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the UROY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.5 | 42.7% |
| Analysts Target Price | 4.5 | 42.7% |
| ValueRay Target Price | 3.1 | -0.3% |
Last update: 2025-09-13 02:44
UROY Fundamental Data Overview
CCE Cash And Equivalents = 20.2m CAD (Cash And Short Term Investments, last quarter)
P/E Forward = 357.1429
P/S = 27.5931
P/B = 2.0207
Beta = 1.876
Revenue TTM = 15.6m CAD
EBIT TTM = -5.29m CAD
EBITDA TTM = -5.17m CAD
Long Term Debt = 157.0k CAD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 52.0k CAD (from shortTermDebt, last quarter)
Debt = 209.0k CAD (Calculated: Short Term 52.0k + Long Term 157.0k)
Net Debt = -12.8m CAD (from netDebt column, last quarter)
Enterprise Value = 575.4m CAD (595.3m + Debt 209.0k - CCE 20.2m)
Interest Coverage Ratio = -42.66 (Ebit TTM -5.29m / Interest Expense TTM 124.0k)
FCF Yield = -3.74% (FCF TTM -21.5m / Enterprise Value 575.4m)
FCF Margin = -137.8% (FCF TTM -21.5m / Revenue TTM 15.6m)
Net Margin = -36.26% (Net Income TTM -5.65m / Revenue TTM 15.6m)
Gross Margin = 19.49% ((Revenue TTM 15.6m - Cost of Revenue TTM 12.6m) / Revenue TTM)
Tobins Q-Ratio = 1.95 (Enterprise Value 575.4m / Book Value Of Equity 294.9m)
Interest Expense / Debt = 1.91% (Interest Expense 4000 / Debt 209.0k)
Taxrate = 21.0% (US default)
NOPAT = -5.29m (EBIT -5.29m, no tax applied on loss)
Current Ratio = 233.5 (Total Current Assets 238.2m / Total Current Liabilities 1.02m)
Debt / Equity = 0.00 (Debt 209.0k / last Quarter total Stockholder Equity 294.9m)
Debt / EBITDA = -0.04 (Net Debt -12.8m / EBITDA -5.17m)
Debt / FCF = -0.01 (Debt 209.0k / FCF TTM -21.5m)
Total Stockholder Equity = 286.8m (last 4 quarters mean)
RoA = -1.91% (Net Income -5.65m, Total Assets 296.1m )
RoE = -1.97% (Net Income TTM -5.65m / Total Stockholder Equity 286.8m)
RoCE = -1.84% (Ebit -5.29m / (Equity 286.8m + L.T.Debt 157.0k))
RoIC = -1.81% (NOPAT -5.29m / Invested Capital 291.5m)
WACC = 9.45% (E(595.3m)/V(595.5m) * Re(9.45%)) + (D(209.0k)/V(595.5m) * Rd(1.91%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 3.05%
Discount Rate = 9.45% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -21.5m)
Revenue Correlation: 22.13 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: -233.9
EPS Correlation: 12.07 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -152.3
Additional Sources for UROY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle